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Patients with atopic dermatitis (AD) manifest a number of 
immune abnormalities which correlate with in vitro defects 
including lymphocyte transformation, chemotaxis, and cy-
totoxicity. Past studies have shown reduced leukocyte cyclic 
3' ,5 '-adenosine monophosphate (cAMP) levels after ex-
posure to adenylate cyclase-active agonists, and we have 
demonstrated that this results from increased catabolism 
due to elevated cAMP-phosphodiesterase activity. These 
results were obtained in preparations containing mixtures 
of lymphocytes and monocytes. In order to determine more 
precisely the cellular site of the defect we have separated 
the leukocytes into lymphocyte- and monocyte-enriched 
preparations using either Percoll-gradient centrifugation or 
adherence isolation. Both techniques yielded over 93% pure 
lymphocytes, whereas the former yielded 64% monocytes 
compared with the latter method which generated 94% 
pure monocytes . Atopic monocytes, obtained by either 
M any immunologic and pharmacologic abnor-malities are associated with atopic dermatitis (AD) [1], and in 1968 Szentivanyi [2] proposed that atopy is a disease in which ,B-adrenergic receptor blockade causes an imbalance of adrenergic and 
cholinergic regulatory influences. 
Initial studies in leukocytes appeared to support his hypothesis, 
showing abnormally diminished cyclic 3 1,S'-adenosine mono-
phosphate (cAMP) responses to ,B-adrenergic agonists [3,4]. 
However, subsequent investigation also revealed reduced leu-
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Abbreviations: 
AC: adenylate cyclase 
AD: atopic dermatitis 
ANAE: a napthyl acetate esterase 
A TP: adenosine triphosphate 
cAMP: cyclic 3',5'-adenosine monophosphate 
CMF: calcium- and magnesium-free (buffer) 
GBSS: Gey's balanced salt solution 
GTP: guanosine 5 '-triphosphate 
HF: Hypaque-Ficoll 
LR: lymphocyte-rich 
MNL: mononuclear leukocyte(s) 
MR: monocyte-rich 
PBS: phosphate-buffered saline 
PD: calcium- and magnesium-deficient PBS 
PDE: phosphodiesterase 
PGE, : prostaglandin E, 
technique, consistently showed elevated phosphodiesterase 
activity compared with those of the nonatopic monocytes. 
Such differences were not evident in lymphocyte prepa-
rations from normal and atopic subjects . In spite of the 
increased rate of cAMP degradation in atopic leukocytes, 
the resting cAMP levels do not differ from those of normal 
subjects. We questioned whether this is caused by increased 
cAMP synthesis and evaluated cellular adenylate cyclase 
activity. We found no evidence in AD cells for an increased 
rate of adenylate cyclase catalysis, either basal activity or 
after stimulation by forskolin . Therefore, the resting cAMP 
levels must have been compensated by other mechanisms. 
Impaired cyclic nucleotide metabolism in atopic monocytes 
may affect a number of immunologic and inflammatory 
reactions and could account for many of the clinical ab-
normalities in atopic diseases.] Invest DerrnatoI87:372-376, 
1986 
kocyte cAMP responses to stimulation by prostaglandin E, (PGE,) 
or histamine [5-7] . These findings indicated a defect not limited 
solely to the ,B-adrenergic receptor. This interpretation was sup-
ported by the failure to detect any consistent abnormalities of 
these receptors by radioligand binding [8,9]. 
A previous study from this laboratory demonstrated elevated 
cAMP phosphodiesterase (PDE) activity in mononuclear leuko-
cytes (MNL) from patients with AD compared with nonatopic 
control subjects or patients with allergic contact dermatitis [10]. 
Thus, the reduced cAMP responses to various agonists could be 
explained by increased cyclic nucleotide catabolism rather than 
by hormone receptor defects . 
These investigations utilized MNL preparations consisting of 
80% lymphocytes and 20% monocytes . The 2 cell types may 
have PDE forms of differing activities and specificities [11,12] 
though conflicting results have been reported [13]. Our studies 
showed that the increased PDE activity in AD MNL had enzyme 
kinetic characteristics similar to those of normal monocytes [10]. 
This indicated that the abnormally high enzyme activity might 
be a result of an enzyme abnormality specifically localized to 
monocytes . Studies on cyclic nucleotide metabolism of mono-
nuclear cells are difficult because of the sensitivity of the system 
to preparative techniques [14]. In view of this technical limitation, 
we have employed 2 different methods of monocyte purification 
to compare the PDE activity in AD and normal cells and to more 
accurately define the MNL subset associated with PDE activity 
in AD. 
Additionally, although atopic MNL have elevated PDE activity 
and diminished responsiveness to cAMP agonists, the resting 
cAMP level is normal [4,6,7]. This suggested that the increased 
PDE catabolic activity in AD leukocytes is balanced by an increase 
in cAMP production. To study this, we assessed the resting or 
stimulated adenylate cyclase (AC) conversion of ATP to cAMP 
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in leukocyte homogenates from normal subj ects and patients 
with AD. 
MATERIALS AND METHODS 
Mononuclear Leukocyte Isolation Heparinized venous blood 
was taken at 9:00 AM from 13 youn g adult patients with typical 
AD [1] , ranging from mild to severe, and from 12 normal healthy 
young adult nonatopic control subj ects. Patients were receiving 
no m edications and had inges ted no caffeine or other meth yl 
xanthine-containing beverages for at leas t 14 h. The MNL were 
sepa rated on H ypaque-Ficoll (HF) gradients (Fico ll-Paq ue, Phar-
macia, Piscataway, N ew Jersey) by centrifuga tion of equal vol-
umes of blood and normal sa line at 450 g for 30 min. The cel ls 
were washed 3 times in Hanks ' calcium- and magnesium-free 
buffer (Hanks' C MF, pH 7.6) at 400 g, 300 g, and 250 g to reduce 
platelet numbers and then were suspended in H anks' CMF at 
20-30 X 10(, cells/ml. 
Perc 011 Separation Continuous gradients were formed by 
combining 7 parts Percoll (Pharmacia) with 6 parts of a double-
s trength phosphate-buffered saline (PBS, pH 7.4). Fifteen-mil-
liliter aliguots were centrifuged in 16 ml polycarbonate tubes 
(no. 257; Sorvall-Dupont Inst., Rockville, M aryland) at 25,000 g 
in an angle head rotor (SS-34) in a Sorvall RC-5B, to form the 
gradients. 
Twenty to thirty million MNL were la yered onto the gradients 
in 1 ml of Hanks ' C MF and spun at 1,000 g in a hanging bucket 
rotor. Two bands were produced: an upper, monocyte-rich (MR) 
fraction and a lower, lymphocyte- rich (LR) fraction as described 
by Gmelig-Meyling and Waldman [15] . 
The cells were washed twice with Hanks ' C MF and resus-
pended at 15-20 X 106/ ml in Hanks' C MF for the aden ylate 
cyclase assay or at 2 X 106/ ml in Gey's balanced salt solution 
(GBSS, Gibco, Grand Island , N ew York) for the POE assay. 
Adherence Separation For ad herence purification of mono-
cytes we processed heparinized blood in a modification of the 
methods of Pawlowski et al [1 6]. Whole blood was washed tw ice 
w ith equal volumes of ca lcium- and magnesium-deficient PBS 
(PO) at 4°C. The blood cells were then resuspended at original 
volume, in PBS containing 0.3 mM EOT A and layered onto 4 
m l HF in 15-ml plas tic tubes (no. 3026, Falcon, Oxnard, Cali-
fornia) for separation of MNL. The MNL were washed and then 
resuspended in 1 ml of PO for co unting. An aliquot was diluted 
with GBSS to a cell count of 1-2 X 106 cell / ml for POE assay. 
The remainder of the cells was diluted to 107/ ml in RPMI-1 640 
(Gibco) containing 15% human AB serum . Three milliliters of 
this suspension were incubated for 2 h in a 60-mm plas tic dish 
(Corning no. 25010, Corning, N ew York) at 37°C in 5% CO2/95% 
air to allow monocyte adherence. 
The supern atant was as pirated and the dishes were rin sed 3 
times with warm GBSS and gentle agitation to remove nonad-
herent cells . A coverslip, previously placed in the bottom of the 
dish, was removed for adherent cell characterization. The adher-
ent cells were washed from the plastic by vigorous pipetting with 
PD. Complete removal and dissociation of monocytes were mon-
itored using an inverted phase microscope. The adherent and 
nonadherent cell populations were:: washed and resuspended at 
1-2 X 106/ ml GBSS for POE assay. 
Cell Characterization Cell viability from both separation 
methods, monitored by trypan blue exclusion, was always grea ter 
than 95%. The MNL, MR, LR, supernatant cells, and adhered 
cells were characterized by Giemsa and a napthyl acetate esterase 
(A NAE) stains [17] , and by latex bead uptake. Values were re-
ported as the mean of the percentages obtained by the 3 methods. 
Cyclic AMP Phosphodiesterase Activity Cells at 1-2 X 106/ml 
in GBSS were passed through 3 freeze-thaw cycles and sonica ted 
fo r 2 min at 4°C by a Braun-Sonic 2000 (B. Braun, Melsungan , 
F. R.G.) set at 50 W. The homogenate was assayed for POE 
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activity using a modifi cation of the procedure of Thompson et 
al [I S]. 
To 200 ILl of the sample was added 200 ILl of substrate con-
taining 1 M cAMP, 20,000 cpm [3H]cAMP (New England Nu-
clear, Boston, M assachusetts) in 40 mM Tris-HCI buffer (pH 8.0) 
containing 3.75 mM ,B-mercaptoethanol and 50 mM M gCh. 
After a lO-min incubation at 30°C the reaction was stopped by 
boiling for 45 s and snap-freezing in an ethanol/ dry ice mixture. 
The mixtures were incubated subsequently with 100 ILl of cobra 
venom (1 mg/ml, Sigma C hemical Co., St. Louis, Missouri) for 
10 min at 30°C and then mixed with 1 ml of AG1 X 2 resin (200-400 
mesh, BioRad, Richmond , California) for 30 min at 4°C. 
The samples were counted in Ready-Solv (Beckman Instru-
ments Corp , San Jose, California) and enzyme activity was ex-
pressed as pmol cAMP hydrolyzed per minute per 106 cells. 
Adenylate Cyclase Assay Cells 2 X 107/ml in Hanks ' CMF 
(pH 7.4) were freeze-thawed 3 times and homogen ized 40 strokes 
in a Oounce homogenizer. Nonstimulated and forsko lin-stimu-
lated AC act ivities were determined using a modification of Sa l-
omon's m ethod [19]. 
The final reaction volume of 50 ILl contained 20 ILl of MNL 
homogenate, 10 ILl offorskolin (10- SM, Sigma) or distilled water, 
10 ILl of 10- 4 M POE inhibitor R020-1 724 (provided by 
Dr. William Scott, Hoffman-LaRoche, Nutley, N ew Jersey), and 
10 ILl of assay cocktail, to give a f111al concentration of reagents 
as follows: creatine phosphate 5 mM, creatine phosphokinase 50 
units / ml, adenosine triphosphate (ATP) 0.5 mM, cAMP 0.05 mM, 
dithiothreitoll mM, bovine serum albumin 0.1 mg/ ml , guanosine 
5 '-triphosphate (GTP) 0.01 mM, and magnesium acetate 5 mM 
(all from Sigma Chemical Co.), and e2p)ATP 2- 6 X 106 cpm 
per assay (New England Nuclea r) in Tris acetate buffer 25 mM 
(pH 7.6). 
Duplicates were incubated for 1 h at 36°C and the reaction 
ended by mixing with 100 ILl of stopping solution 'composed of 
2% lauryl sulfate, 45 mM ATP, and 1.3 mM cAMP (Sigma). 
Assay blanks were prepared by adding cell homogenate after 
stopping solution and by omitting the homogenate completely. 
All tubes contained 50 ILl of [3H]cAMP to monitor cAMP re-
covery. Cyclic AMP was recovered by passing the 200-ILI aliquots 
plus 1 ml deionized water through Dowex AGWX4 columns 
(200-400 mesh BioRad). After further flushing with 1 ml of water, 
the Oowex columns were placed over alumina columns and washed 
with 9 ml of deionized water. The alumina columns were then 
flushed with 6 n11 of imidazole buffer (pH 7.3) and the 6-ml eluates 
were collected in vials containing 14 ml of scintillation fluid (Ready-
Solv, Beckman Instruments, Inc., Fullerton, CAl . The recovery 
of cAMP was 75-90% and the specific activity of AC was ex-
pressed as pmol cAMP produced per minute per 106 cells. 
RESULTS 
Mononuclear Leukocyte Subpopulations (Table I) H ypague-
Ficoll separation yielded lymphocytes and monocytes of greater 
than 99% purity in yields consistently exceeding SO% of total 
Table I. Composition of Atopic and Normal Mononuclear 
Leukocyte (MNL) Subsets from Hypaque-Ficoll, 
Percoll-Separated Lymphocyte-rich (LR) and Monocyte-rich 
(MR) Cell Fractions and Adherence-Separated Monocyte and 
Lymphocyte Preparations" 
MNL 
MR 
LR 
Adherent 
N onadherent 
Atopic Dermatitis 
70 ± 3.75% (L) 
64 ± 4.5% (M) 
94 ± 2% (L) 
94 ± 5% (M) 
91 ± 3.3% (L) 
"Mean % ± SEM of lymphocy tes (L) or monocy tes (M). 
N orm al 
70 ± 2.5% (L) 
60 ± 4.9% (M) 
93 ± 2.6% (L) 
93 ± 3.4% (M) 
90 ± 4.6% (L) 
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MNL and 95% of monocytes. We found no differences between 
the proportions of monocytes and lymphocytes in the MNL, or 
in Percoll-enriched LR and MR preparations from AD patients 
and no rmal nonatopi c subjects. The MNL preparations contained 
30% monocytes and this was increased to 64% in the MR frac-
tions. The LR fractions were composed of an average of 94% 
lymphocytes. Mea n total cell recovery was 92.8% with 90.4% 
monocyte and 93.8% lymphocyte recovery from the Percoll gra-
dients. There were no differences in recoveries of normal and AD 
cell s. 
The adherence method provided monocyte preparations of 94% 
and 93% purity in preparations from AD patients and normal 
subjects, respectively. Seventy to eighty percent of the MNL 
remained non adherent and these supernatant cells consisted of 
91 % and 90% lymphoc;ytes in AD and normal subsets, respec-
tively. In addition, som~ preparations were examined for non-
phagocytic cells bearing surface immunoglobulin . These revealed 
that the nonadherent cells contained approximately 10% B cells, 
compared with only 2% B cell contamination of adherent cells. 
No differences in percentages were seen between the AD (n = 
2) and normal samples examined (n = 4). 
In contrast, the MR fraction contained 11 % B cells whereas 
the LR fraction contained 3% B cells. Again, no differences were 
apparent between the AD and normal preparations. 
Phosphodiesterase Activity 
Pereoll Separation: The PDE activity varied, depending on the 
subpopulation examined (Table II) . Normal and AD subjects 
showed no significant difference between MNL and MR prepa-
rations. The POE activity in LR fractions was significantly less 
than that in MNL and MR populations (p < 0.005) but no sig-
nificant difference existed between AD and normal LR cells. In 
contras t the AD preparations showed a significantly higher ac-
tivity in both MNL fractions compared with normal (p < 0.005). 
We observed that , in spite of a higher proportion of monocytes, 
the POE activity of the Percoll-separated MR fraction was similar 
to that of the MNL. Thus, there appeared to be a Percoll-induced 
reduction in PDE activity. To evaluate this possibility we sub-
jected MNL to Percoll separation and then recombined the 2 
bands to produce the original MNL constitution . The PDE ac-
tivity in HF-separated MNL was 0.13 pmoilmin/106 cells, whereas 
the MNL that had passed throu gh Percoll had their PDE activity 
red uced by 25% to 0.099 pmol/min/l06 cells. 
Adherence Separation: Adherence separation of monocytes in-
creased the purity of those cells. Adherent cells were 94% mono-
cytes in atopic preparations and 93% in normal preparations, as 
shown in Table I. These values were considerably higher than 
those obtained from the Percoll separation (Table I). We com-
pared 4 AD subjects and 6 normal subjects (Table III) . 
Phosphodiesterase activity in MNL populations prior to ad-
heren ce was significantly higher in AD patients compared with 
normal subjects. This difference between atopics and normals was 
much g reater in the purified, adherent monocytes. The atopic 
POE was 5-fold hi gher (0.207 ± 0.1 compared with 0.042 ± 
0.02 pmol/min/l06 cells) than in normal cells (p < 0.005). In 
addition, a significant but smaller elevation of PDE activity was 
seen in the nonadherent cells (p < 0.025), but these cells had 
Table II. Cyclic AMP Phosphodiesterase Activity of Atopic 
Dermatitis (AD) and Normal Mononuclear Leukocyte Subsets" 
Mononuclear leukocyte 
M onocyte-rich 
Lymphocyte-rich 
"pmoi/ll1 inIl O" :!: SEM. 
'p < 0.005. 
AD (n = 9) 
0.069 ± 0.006" 
0.052 ± 0.008" 
0.0067 ± 0.002 
Normal 
(n = 8) 
0.026 ± 0.005 
0.019 ± 0.005 
0.0062 ± 0.001 
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Table III. Comparison of Phosphodiesterase Activity of 
Atopic and Normal Mononuclear Leukocyte Subsets Separated 
by Adherence to Plastic Petri Dishes" 
Mononuclear leukocyte" 
Nonadherent" 
Adherent' 
"pill oil ll1inl 10" cells:!: SEM. 
"p < 0.025. 
'p < 0.005. 
Atopic Dermatitis 
(n = 4) 
0.071 ± 0.013 
0.074 ± 0.012 
0.207 ± 0.05 
Normal 
(n = 6) 
0.035 ± 0.005 
0.036 ± 0.008 
0.042 ± 0.008 
considerably more contamination by monocytes in both normal 
(10%) and AD (9%) preparations and contained the majority of 
B cells. Similar 6-7% monocyte contamination in Percoll-pre-
pared cells (Table I) may have been obscured by the observed 
reduction of PDE by Percoll separations and the lower B cell 
nLl1nbers. 
Adenylate Cyclase Activity In spite of the marked elevation 
of atopic MNL PDE, the resting cAMP level does not differ from 
that of normal MNL [7] . We questioned whether the increased 
PDE was balanced by an elevation of AC activity. To investigate 
this possibility we measured the AC activity of MNL, MR, and 
LR fractions . Insufficient numbers of adherence-purified mono-
cytes were obtainable for the adenylate cyclase assay. In both AD 
and normal preparations, the MR cells had basal AC significantly 
higher than that found in the LR fraction (Table IV) (p < 0.005). 
However, there were no differences in the AC activities between 
normal and AD cell preparations. Although the atopic MR frac-
tion had a slightly higher AC activity, this was not statistically 
significant. 
Forskolin, a catalytic unit stimulator of AC, was studied to 
evaluate stimulated enzyme activity in the various leukocyte prep-
arations. Dose response studies of MNL showed optimal stim-
ulation at 10 - 5 M concentrations and this concentration was used 
in subsequent studies. We observed significant differences be-
tween basal and forskolin-stimulated AC activities . There were 
no differences in maximal AC activity between atopic and normal 
leukocyte preparations (Table IV). These AC studies utilized only 
homogenate preparations due to limitations on materials . In 2 
cases where adequate cells were available, we compared AC ac-
tivity in 106,000 g sedimented membrane preparations. Forskolin-
stimulated values based on protein concentrations showed mean 
7-fold increases in both membrane and homogenate activities, 
ind!cating that t~e latter provided reliable preparations for com-
panson. 
DISCUSSION 
This study confirms the elevated PDE activity in MNL from 
patients with AD. These data clarify our previous kinetic studies 
which showed kinetic similarities between the PDE with in-
creased activity from AD MNL preparations and the PDE from 
normal monocytes. 
Our results demonstrate that monocytes from patients with 
AD have elevated PDE activity when compared with normal 
control subjects. The difference between AD and controls was 
magnified when monocyte preparations of greater purity were 
obtained by adherence. 
It is. apparent from the data that preparative methods affect 
PDE activity and we have shown a 25% inhibitory effect of 
Percoll centrifugation on PDE activity. The similar values ofPDE 
activity for nonadherent cells and MNL suggests a possible stim-
ulatory effect on PDE activity during the 2-h adherence of MNL 
and it is clear that both AD and control samples were affected in 
a similar manner. 
However, in spite of the differing effects of the 2 cell separation 
methods on PDE activity, both monocyte preparations from AD 
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Table IV. Basal- and 10- 5 M Fo rskolin-Stimulated Adenylate Cyclase Activity of Atopic Derm atitis (AD) and N ormal 
Percoll-Separated Mononuclear Leukocyte Subsets" 
Mononuclea r leukocyte 
Monocyte-rich 
Lymphocyte-rich 
' pmol/min I10" cells ± SEM. 
Basal 
7.3 ± 1. 5 
9.0 ± 2.4 
1. 4 ± 0.5 
' Com pa rison between basal- and forsko lin-stimulatcd level. 
AD (n = 9) 
(p < 0.005)b 
patients showed va lues signifi cantly higher than th ose of control 
samples treated identi ca lly. Further, the results illustrate the im-
portance of em ploying different methods of purifi cation of mono-
nuclea r subsets when examining PDE activity. The PDE activity 
of AD lymphocy tes compared with normals is less clea r because 
lymphocytes obtained by the 2 preparative meth ods showed a 
signifi cant difference by one method only. The LR fraction and 
the nonadh erent cells both comprised lymphocytes predomi-
nantly and had lower PDE activity than the corres ponding mono-
cyte preparation. How ever, no difference between AD and nor-
m al lymphocy tes was found in the 94% LR preparations , w hereas 
the less pure non adherent sam pies showed signifi cantly higher 
PDE activity in AD cells. 
Although the higher proportion of contaminating monocytes 
in the nonadherent lymphocy te preparations would be seen to be 
the initi al explanation , the nonadherent cells appear to contain a 
higher proportion of B cells than the LR fracti on . Normal B cells 
have been repo rted as having high PDE activity and although the 
P DE acti vity of B cells in AD is unknown at present, an eleva ted 
PDE has been implica ted by the suppression of AD spontaneous 
IgE production by specific PDE inhibitors [20]. Thus, our data 
cann ot exclude some eleva tion ofl ymphocyte, particularl y B lym-
phocyte, PDE acti vity in AD . 
Although atopic monocytes clearly have elevated cAMP ca-
tabolism , several studies have fa il ed to demonstra te a difference 
in restin g cAMP levels in leukocytes of normal and AD subj ects 
[4,6,7]. This may indicate that the des truction of cAMP by PDE 
is balanced by increased producti on of cAMP by AD leukocytes. 
O ur present data do not verify this proposal. We found no con-
sistent o r signifi cant increase in either basal o r maximal AC ac-
tivity in any of the preparations, whether mixed MNL, LR, or 
MR. Un fo rtun ately, the number 0'[ cells required for the AC 
assay precluded the use of a second method fo r preparing the 
leukocyte subsets to confirm the findin gs obtained on Percoll-
purified prepara ti ons. 
Abnormalities of AD monocy tes have been implicated in sev-
eral recent studies [21,22] and cyclic nucleotides may modulate 
several in vitro immune fun ctions [23,24]. Herlin and Kragballe 
[21] associated impaired monocyte cyclic AMP responses with 
diminished monocyte cytotoxicity in atopi cs. O ur findin gs of 
increased PDE acti vity in this group of cells would sa tisfactorily 
explain their findin gs of diminished cAMP responsiveness. Im-
paired cyclic nucleotide metabolism in monocytes could affect a 
n umber ' o f immune fun ctions including phagocytosis, antigen 
p resentation , and responses to Iymphokines [25) . These in turn 
could account for some of the observed immunologic abnor-
malities in AD [1]. 
In summary, we have demonstrated that atopic monocytes have 
elevated PDE activity in the absence of a similar increase in resting 
o r stimulated AC activity . Understandin g the basis of cyclic nu-
cleotide abnormalities ill AD m ay allow clarifica tion of the many 
pharm acologic and immunologic defects associated with atopic 
disease. 
Forskolin 
77.4 ±9.7 
84.0 ± 1.5 
24. 0 ± 5.3 
Basa l 
7.6 ± 2.6 
5.9 ± 1.6 
2.3 ± 0. 7 
N ormal (n 8) 
Forskolin 
68. 19 ± 13.74 
62.0 ± 15.0 
28.6 ± ' 6.4 
(p < 0.005)b 
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